Shield Therapeutics PLC banner

Company Overview

Business Description

Sector
Health Care
Industry
Pharmaceuticals
Headquarters
United Kingdom UK
Employees
63
IPO date
Feb 26, 2016

Shield Therapeutics is a specialty pharmaceutical company focused on treating iron deficiency and iron deficiency anaemia. Its main product is an oral iron medicine designed for patients who cannot tolerate standard iron pills or who need a different way to replace iron. The company sells prescription medicine to healthcare providers and pharmacies, so the real customers are doctors, hospitals, and patients using the treatment under medical supervision.

The business makes money by selling its iron medicine through direct sales and commercial partnerships in different markets. In some places it works with partners that handle marketing, distribution, and sales, while Shield keeps a share of the economics through product sales or licensing-style agreements. That means the company sits at a narrow point in the healthcare value chain: it does not run hospitals or make broad drug portfolios, but instead focuses on one specific therapy area where it can build expertise around a single branded product.

What makes Shield different is its focus on a common but often under-treated medical problem rather than a wide range of drugs. Iron deficiency affects many patients, yet traditional iron treatments can be hard to take or less convenient. Shield’s business is built around offering a prescription alternative and then commercializing it through specialist pharma channels, which is why its success depends on physician adoption, pharmacy access, and partner execution rather than on mass consumer sales.

Shield Therapeutics PLC Investor Relations

Address
Northern Design Centre Studio 6, 3Rd Floor Baltic Business Quarter, Gateshead Quays
Gateshead, Tyne and Wear
United Kingdom

Business Segments

Iron deficiency medicine

Shield Therapeutics develops and sells medicines for iron deficiency and iron deficiency anemia, led by its oral iron treatment for patients who cannot use standard iron supplements well.

Customers and revenue model

Management

Mr. Anders Lundstrom

Interim CEO & Independent Non-Executive Director

Biography unavailable

Dr. Christian Schweiger M.D., Ph.D.

Co-Founder & Non Executive Director

Biography unavailable

Mr. Santosh Shanbhag

Chief Financial Officer

Biography unavailable

Ms. Lucy Kate Huntington-Bailey

General Counsel & Company Secretary

Biography unavailable

Ms. Suzanne Wood

Group HR Director

Biography unavailable

Ms. Carol Akinola

Head of Pharmacovigilance & Medical Information

Biography unavailable

Mr. Andrew Hurley

Chief Commercial Officer

Biography unavailable

Kate Armanetti

Senior Director of People & Culture

Biography unavailable

1 / 8